The Search for Biomarkers of Alzheimer's Disease in Down Syndrome (2025) скачать в хорошем качестве

The Search for Biomarkers of Alzheimer's Disease in Down Syndrome (2025)

Adults with Down syndrome are at exceptionally high risk for Alzheimer’s disease. Virtually all individuals develop the neuropathology consistent with a post-mortem Alzheimer’s diagnosis, including amyloid plaques, neurofibrillary tangles and granulovacuolar degeneration by the mid to late 40’s. The conversion to dementia in Down syndrome is often confounded by other factors, including varying levels of baseline intellectual disability and associated medical and psychiatric conditions. As a result, there is a considerable variability in the age of dementia onset, ranging from the late 40’s to over age 70. The Alzheimer’s Biomarker Consortium – Down Syndrome is a longitudinal cohort study of over 500 adults with Down syndrome, now in its 9th year. Handen will share some of the study’s most recent findings that help us to better understand the course and relationship of key biomarkers of Alzheimer’s , their impact on cognition, and how they provide potential targets for upcoming prevention trials.